/PRNewswire/ Rigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq: RIGL) today announced that it has entered into a definitive agreement to acquire the U.S. rights.
Rigel Pharma (RIGL) Acquires U S Rights to GAVRETO from Blueprint Medicines (BPMC) streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
AMGEN HIGHLIGHTS HEMATOLOGY PORTFOLIO AT ASH 2023 streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Company to Feature 17 Company-Sponsored and Nine Collaborative Abstracts in Oncology and Hematology
Hematology Presentations Include New Data from the Phase 3 and Continuation Trials Supporting.
Company AnnouncementTEPKINLY® (epcoritamab) is the first and only subcutaneous bispecific antibody approved as a monotherapy for adult patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapyConditional marketing authorization approval from the Eur.